Download PDF
Klin Monbl Augenheilkd 2013; 230(2): 133-140
DOI: 10.1055/s-0032-1328095
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Stellenwert der Kombinationstherapie in der medikamentösen Glaukombehandlung

Combination Therapy in the Medical Treatment of Glaucoma
A. Hommer
Augenheilkunde, Ordination, Vienna, Austria
› Author Affiliations
Further Information

Publication History

eingereicht 18 September 2012

akzeptiert 26 November 2012

Publication Date:
20 January 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Eine Kombinationstherapie des Glaukoms ist immer dann indiziert, wenn der angestrebte Zieldruckwert mit einer Monotherapie nicht erreicht wird, und/oder die Glaukomerkrankung fortschreitet oder eine Konversion von einer okulären Hypertension zu einem Glaukom auftritt. Seit einiger Zeit stehen für eine Kombinationstherapie auch zahlreiche Fixkombinationen aus zwei unterschiedlichen Wirkstoffen zur Verfügung, die die Anwendung für die Patienten im Vergleich zu nicht fixen Präparatekombinationen bedeutend erleichtern: Fixkombinationen reduzieren die tägliche Tropffrequenz. Dies kann die Adhärenz verbessern. Fixkombinationen enthalten ferner normalerweise weniger toxische Konservierungsstoffe im Vergleich zu nicht fixen Präparatekombinationen. Ferner entfällt bei Fixkombinationen auch die potenzielle Gefahr eines „Auswaschens“ des zuerst getropften Glaukompräparats durch eine zu kurze Wartezeit zwischen den einzelnen Tropfenapplikationen. In dieser Übersichtsarbeit werden die wichtigsten Aspekte einer fixen und nicht fixen Kombinationstherapie des Glaukoms diskutiert, wobei der Schwerpunkt auf den fixen Präparatekombinationen liegt. In Deutschland sind derzeit Fixkombinationen mit den Zusammensetzungen Dorzolamid/Timolol (FCDT), Brinzolamid/Timolol (FCBRINT), Latanoprost/Timolol (FCLT), Travoprost/Timolol (FCTT), Bimatoprost/Timolol (FCBIMT), Brimonidin/Timolol (FCBT), Pilocarpin/Timolol (FCPT) und Pilocarpin/Metipranolol (FCPM) zur Behandlung von Patienten mit Glaukom oder okulärer Hypertension zugelassen. Die Ergebnisse klinischer Studien, in denen diese Fixkombinationen mit den Einzelwirkstoffen, mit den entsprechenden nicht fixen Kombinationen, sowie untereinander verglichen werden, werden, soweit verfügbar, in dieser Übersichtsarbeit zusammenfassend dargestellt.

Abstract

A combination of antiglaucoma medications is indicated if monotherapy is not sufficient to achieve the predefined target pressure and/or in case of a progression of glaucomatous damage or conversion from ocular hypertension to glaucomatous optic neuropathy. Most recently many fixed combinations with two active compounds have become available for the medical treatment of glaucoma. Compared to non-fixed combinations, these drugs offer a much easier use for the patients. Fixed combinations have to be applied less frequently which may improve adherence. Furthermore, they most likely contain a lower amount of toxic preservatives compared to non-fixed combinations. And finally, fixed combinations may eliminate the risk of a “washout” of the first medication by using the second product of a non-fixed combination too soon after the first drop has been installed. This review aims to examine the most important aspects of IOP-lowering fixed and non-fixed combinations in glaucoma management with a clear focus on the results obtained with fixed combinations. In Germany, fixed combinations with the compositions dorzolamide/timolol (FCDT), brinzolamide/timolol (FCBRINT), latanoprost/timolol (FCLT), travoprost/timolol (FCTT), bimatoprost/timolol (FCBIMT), brimonidine/timolol (FCBT), pilocarpine/timolol (FCPT) and metipranolol/timolol (FCMT) are approved for the medical management of glaucoma and ocular hypertension. The results of clinical studies comparing fixed combinations with their active ingredients and with the corresponding non-fixed combinations will be discussed. Furthermore – if available – the results of direct comparisons of the efficacy and safety of different IOP-lowering fixed combinations are summarised.

Schlüsselwörter

intraokularer Druck - Kombinationstherapie - Fixkombinationen - Glaukom

Key words

intraocular pressure - combination therapy - fixed combinations - glaucoma
 

  • Literatur

  • 1 Medizinische Medien Informations GmbH Hrsg. Gelbe Liste Pharmindex – Ophthalmologen 2012. Neu Isenburg: MMI; 2012
    Google Scholar
  • 2 Schwabe U, Paffrath D Hrsg. Arzneiverordnungs-Report 2011. Aktuelle Daten, Kosten, Trends und Kommentare. Heidelberg: Springer-Verlag; 2012
    CrossrefGoogle Scholar
  • 3 Stewart WC, Kruft B, Nelson LA et al. Ophthalmologist attitudes regarding fixed combination treatment for glaucoma in the European Union. Eur J Ophthalmol 2009; 19: 588-593
    PubMedGoogle Scholar
  • 4 European Glaucoma Society (EGS) Hrsg. Terminology and Guidelines for Glaucoma. 3rd. edition. Savona: Dogma; 2008
    Google Scholar
  • 5 Clinical Trials Gov – A service of the US National Institutes of Health Im Internet: http://clinicaltrials.gov/ct2/results?term=Brinzolamide+and+Brimonidine Stand: 30.08.2012
    PubMed
  • 6 Clinical Trials Gov – A service of the US National Institutes of Health Im Internet: http://clinicaltrials.gov/ct2/results?term=Travoprost+and+Brinzolamide Stand: 30.08.2012
    PubMed
  • 7 Neufeld AH. Experimental studies on the mechanism of action of timolol. Surv Ophthalmol 1979; 23: 363-370
    CrossrefPubMedGoogle Scholar
  • 8 Dailey RA, Brubaker RF, Bourne WM. The effects of timolol maleate and acetazolamide on the rate of aqueous formation in normal human subjects. Am J Ophthalmol 1982; 93: 232-237
    PubMedGoogle Scholar
  • 9 Dinslage S, Hueber A, Diestelhorst M et al. The influence of Latanoprost 0.005 % on aqueous humor flow and outflow facility in glaucoma patients: a double-masked placebo-controlled clinical study. Graefes Arch Clin Exp Ophthalmol 2004; 242: 654-660
    CrossrefPubMedGoogle Scholar
  • 10 Toris CB, Gleason ML, Camras CB et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995; 113: 1514-1517
    CrossrefPubMedGoogle Scholar
  • 11 Costagliola C, dellʼOmo R, Romano MR et al. Pharmacotherapy of intraocular pressure – part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother 2009; 10: 2859-2870
    CrossrefPubMedGoogle Scholar
  • 12 Alvarado JA, Iguchi R, Martinez J et al. Similar effects of selective laser trabeculoplasty and prostaglandin analogs on the permeability of cultured Schlemm canal cells. Am J Ophthalmol 2010; 150: 254-264
    CrossrefPubMedGoogle Scholar
  • 13 Grierson I, Lee WR, Abraham S. Effects of pilocarpine on the morphology of the human outflow apparatus. Br J Ophthalmol 1978; 62: 302-313
    CrossrefPubMedGoogle Scholar
  • 14 Toris CB, Gleason ML, Camras CB et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol 1995; 113: 1514-1517
    CrossrefPubMedGoogle Scholar
  • 15 Serle JB, Wang RF, Mittag TW et al. Effect of pilocarpine 4 % in combination with latanoprost 0.005 % or 8-iso prostaglandin E2 0.1 % on intraocular pressure in laser-induced glaucomatous monkey eyes. J Glaucoma 2001; 10: 215-219
    CrossrefPubMedGoogle Scholar
  • 16 Toris CB, Zhan GL, Zhao J et al. Potential mechanism for the additivity of pilocarpine and latanoprost. Am J Ophthalmol 2001; 131: 722-728
    CrossrefPubMedGoogle Scholar
  • 17 Toris CB, Alm A, Camras CB. Latanoprost and cholinergic agonists in combination. Surv Ophthalmol 2002; 47 (Suppl. 01) S141-S147
    CrossrefPubMedGoogle Scholar
  • 18 Clinical Trials Gov – A service of the US National Institutes of Health Im Internet: http://clinicaltrials.gov/ct2/results?term=Tafluprost+and+Timolol Stand: 30.08.2012
    PubMed
  • 19 Boyle JE, Ghosh K, Gieser DK et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology 1998; 105: 1945-1951
    CrossrefPubMedGoogle Scholar
  • 20 Clineschmidt CM, Williams RD, Snyder E et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology 1998; 105: 1952-1959
    CrossrefPubMedGoogle Scholar
  • 21 Kaback M, Scoper SV, Arzeno G et al. Brinzolamide 1 %/Timolol 0.5 % Study Group. Intraocular pressure-lowering efficacy of brinzolamide 1 %/timolol 0.5 % fixed combination compared with brinzolamide 1 % and timolol 0.5 %. Ophthalmology 2008; 115: 1728-1734
    CrossrefPubMedGoogle Scholar
  • 22 Higginbotham EJ, Feldman R, Stiles M et al. Fixed Combination Investigative Group. Latanoprost and timolol combination therapy vs. monotherapy: one-year randomized trial. Arch Ophthalmol 2002; 120: 915-922
    CrossrefPubMedGoogle Scholar
  • 23 Pfeiffer N. European Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefes Arch Clin Exp Ophthalmol 2002; 240: 893-899
    CrossrefPubMedGoogle Scholar
  • 24 Sherwood MB, Craven ER, Chou C et al. Twice-daily 0.2 % brimonidine-0.5 % timolol fixed combination therapy vs. monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006; 124: 1230-1238
    CrossrefPubMedGoogle Scholar
  • 25 Brandt JD, Cantor LB, Katz LJ et al. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma 2008; 17: 211-216
    CrossrefPubMedGoogle Scholar
  • 26 Barnebey HS, Orengo-Nania S, Flowers BE et al. The safety and efficacy of travoprost 0.004 %/timolol 0.5 % fixed combination ophthalmic solution. Am J Ophthalmol 2005; 140: 1-7
    PubMedGoogle Scholar
  • 27 Hutzelmann J, Owens S, Shedden A et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and concomitant administration of dorzolamide and timolol: a clinical equivalence study. Br J Ophthalmol 1998; 82: 1249-1253
    CrossrefPubMedGoogle Scholar
  • 28 Strohmaier K, Snyder E, DuBiner H et al. The efficacy and safety of the Dorzolamide–Timolol combination verses the concomitant administration of its components. Ophthalmology 1998; 105: 1936-1944
    CrossrefPubMedGoogle Scholar
  • 29 Diestelhorst M, Larsson LI. European Latanoprost Fixed Combination Study Group. A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol 2004; 88: 199-203
    CrossrefPubMedGoogle Scholar
  • 30 Diestelhorst M, Larsson LI. European-Canadian Latanoprost Fixed Combination Study Group. A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology 2006; 113: 70-76
    CrossrefPubMedGoogle Scholar
  • 31 Hommer A. Ganfort Investigators Group I. A double randomized, parallel comparison of a fixed combination of bimatoprost 0.03 %/timolol 0.5 % with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol 2007; 17: 53-62
    PubMedGoogle Scholar
  • 32 Hughes BA, Bacharach J, Craven RE et al. A three-month, multicentre, double masked study of the safety and efficacy of travoprost 0.004 %/timolol 0.5 % ophthalmic solution compared to travoprost 0.004 % ophthalmic solution and timolol 0.5 % dosed concomitantly in subjects with open angle or ocular hypertension. J Glaucoma 2005; 14: 392-399
    CrossrefPubMedGoogle Scholar
  • 33 Schuman JS, Katz GJ, Lewis RA et al. Efficacy and safety of a fixed combination of travoprost 0.004 %/timolol 0.5 % ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005; 140: 242-250
    PubMedGoogle Scholar
  • 34 Goñi FJ. Brimonidine/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005; 15: 581-590
    PubMedGoogle Scholar
  • 35 Centofanti M, Oddone F, Gandolfi S et al. Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. Am J Ophthalmol 2010; 150: 575-580
    CrossrefPubMedGoogle Scholar
  • 36 Vaede D, Baudouin C, Warnet JM et al. [Preservatives in eye drops: toward awareness of their toxicity]. J Fr Ophtalmol 2010; 33: 505-524
    CrossrefPubMedGoogle Scholar
  • 37 Liang H, Pauly A, Riancho L et al. Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. Br J Ophthalmol 2011; 95: 869-875
    CrossrefPubMedGoogle Scholar
  • 38 Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol 2012; 153: 1-9
    CrossrefPubMedGoogle Scholar
  • 39 Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res 2011; 36: 391-398
    CrossrefPubMedGoogle Scholar
  • 40 Labbé A, Pauly A, Liang H et al. Comparison of toxicological profiles of benzalkonium chloride and polyquaternium-1: an experimental study. J Ocul Pharmacol Ther 2006; 22: 267-278
    CrossrefPubMedGoogle Scholar
  • 41 Paimela T, Ryhänen T, Kauppinen A et al. The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells. Mol Vis 2012; 18: 1189-1196
    PubMedGoogle Scholar
  • 42 Kitazawa Y, Smith P, Sasaki N et al. Travoprost 0.004 %/timolol 0.5 %-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. Eye (Lond) 2011; 25: 1161-1169
    CrossrefPubMedGoogle Scholar
  • 43 Nordstrom BL, Firedman DS, Mozaffari E et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005; 140: 598-606
    PubMedGoogle Scholar
  • 44 Sleath B, Robin AL, Covert D et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology 2006; 113: 431-436
    CrossrefPubMedGoogle Scholar